Compare EMO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMO | NEO |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2008 |
| Metric | EMO | NEO |
|---|---|---|
| Price | $50.25 | $8.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | 47.2K | ★ 1.3M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 6.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.54 | $4.72 |
| 52 Week High | $54.90 | $13.74 |
| Indicator | EMO | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 36.28 | 46.71 |
| Support Level | $46.50 | $7.33 |
| Resistance Level | $54.44 | $8.89 |
| Average True Range (ATR) | 1.33 | 0.38 |
| MACD | -0.44 | 0.17 |
| Stochastic Oscillator | 8.07 | 76.21 |
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.